Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of Vonoprazan Versus Intravenous Proton Pump Inhibitors for Prevention of Rebleeding in High Risk Peptic Ulcers Bleeding After Successful Endoscopic Hemostasis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: EARLY_PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* High risk peptic ulcers bleeding (Forrest class Ia,Ib,IIa,IIb)~Exclusion Criteria:~* Patients were not achieve endoscopic hemostasis~* End stage cancer disease~* Severe critical illness and ICU setting~* Uncorrectable coagulopathy~* Pregnancy or breast feeding~* Allergy to PPIs or Vonoprazan

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Vonoprazan (Type: EXPERIMENTAL): Vonoprazan 20 mg oral every 12 hours (total 72 hours) then vonoprazan 20 mg oral once daily for 28 days
- PPIs (Type: ACTIVE_COMPARATOR): PPIs IV infusion for 72 hours then oral PPIs twice per day for 28 days

Based on this trial design, predict the completion outcome and termination type (if applicable).